聚丙烯酰胺水凝胶注射隆乳术后并发胸腔内凝胶移位1例

张庆雪 张莹莹 高东程 赵硕 李靖若

郑州大学第一附属医院乳腺外科,郑州 450052

通信作者:李靖若,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

DOI:10.3760/cma.j.issn.1671-0290.2023.02.023

755nm 翠绿宝石皮秒激光治疗口唇部位色素痣1例

任荣鑫 赵红艺

北京医院整形外科 国家老年医学中心 中国医学科学院老年医 学 研 究 院,北 京

100730

通信作者:赵红艺,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

DOI:10.3760/cma.j.issn.1671-0290.2023.03.020

Statin heart benefits outweigh diabetes risks

Treatment with high-intensity statins, such as atorvastatin 20 mg upwards, results in a 36% proportional increase in new type 2 diabetes diagnoses compared to placebo, with the majority of the new diabetes occurring in people already close to the diabetes glycaemic threshold, according to this meta-analysis of participant-level data from the Cholesterol Treatment Trialists’ Collaboration published in The Lancet Diabetes & Endocrinology. A smaller 10% proportional increase occurs with low- or moderate-intensity statins. Although previous meta-analyses of summary data from the statin trials have highlighted this increased risk, they could not fully quantify the size and timing of increases or determine who is at greatest risk. People with pre-existing diabetes treated with statins are also at risk of worsening glycaemia, particularly with high-intensity statins. However, the benefits of statins in reducing cardiovascular events in those at high risk far outweigh the impact of these increases in incident type 2 diabetes, so this study should not change prescribing habits. Nonetheless, it reminds us of the importance of counselling regarding increasing glycaemia risk and of encouraging lifestyle discussions around weight, eating patterns, sleep and physical activity, which can not only reduce the risk of type 2 diabetes but also improve the cardiovascular risk the statin is being used to treat.

Pam Brown

GP in Swansea

Citation: Brown P (2024) Diabetes Distilled: Statin heart benefits outweigh diabetes risks. Diabetes & Primary Care 26: [Early view publication]

ActivHeal® PHMB Foam dressing range: a product evaluation

Effective management of exudate is crucial for ensuring timely wound healing. Summarised in this product focus are 11 clinical studies (incorporating the experience of 179 patients), indicating that the ActivHeal® PHMB Foam dressing range (Advanced Medical Solutions Ltd.) is effective at treating infected wounds, managing wound exudate, debridement/wound cleansing, and enhancing the quality of life in patients with a various wound types, including venous leg ulcers (VLU), diabetic foot ulcers (DFU), pressure ulcers (PU), burns and postoperative surgical wounds. The use of the antimicrobial agent polyhexamethylene biguanide (PHMB) provides an effective defence against a broad spectrum of microorganisms, including antibiotic-resistant microorganisms, commonly associated with wound colonisation and infection. This evaluation does not aim to be a systematic or narrative review but rather a selection of the most pertinent publications summarising the clinical evidence supporting ActivHeal PHMB Foam range for the treatment of various chronic and acute wounds.

Rebecca Forder

Senior Clinical Research Manager, Advanced Medical Solutions, Winsford, UK

Alan A Rogers

Independent Wound Care Consultant, Flintshire, UK

Karen Ousey

Professor of Skin Integrity, Director for the Institute of Skin Integrity and Infection Prevention, Department of Nursing and Midwifery, University of Huddersfield, Huddersfield, UK

Mark G Rippon

Visiting Clinical Research Fellow, Institute of Skin Integrity and Infection Prevention, University of Huddersfield, Queensgate, Huddersfield, UK

Key words

• ActivHeal PHMB Foam
• Exudate management
• Infected wounds
• Wound healing

Declaration of interest

This publication was supported by Advanced Medical solutions.

Negative pressure wound therapy with vancomycin wound instillation: a case report

Negative pressure wound therapy (NPWT) supports the healing process by removing fluid and drawing out the infection from a wound, promoting the growth of new tissue. The device works by providing and distributing negative pressure evenly across the wound bed, either through the application of an open cell foam or a gauze dressing. NPWT provides a warm, moist wound bed while removing wound fluid that contains factors that inhibit cell growth, enhances wound oxygenation and improves the flow of blood and nutrients to the wound. NPWT also creates mechanical forces that influence the wound macroscopically, inducing cell proliferation, cell migration to the wound and angiogenesis. For infected wounds, the device can be used to instil antibiotics. In this article, a 57-year-old Caucasian woman with respiratory failure developed sepsis secondary to an intra-abdominal infection with abscess. Vancomycin 1mg/mL wound instillation, instilled as 100mL every 3 hours with a dwell time of 10 minutes, was administered concomitantly with intravenous vancomycin in the successful management of this patient.

Alison Bunnell

Doctor of Pharmacy Candidate 2022, North Dakota State University, Fargo, ND, USA

Erin Beauclair

Doctor of Pharmacy Candidate 2022, North Dakota State University, Fargo, ND, USA

Breanna Jones

Doctor of Pharmacy, Pharmacy Department, Sanford Medical Center Fargo, Fargo, ND, USA

Emily Greenstein

Advanced Practice Registered Nurse and Certified Nurse Practitioner, Wound Care, Sanford Medical Center Fargo, Fargo, ND, USA

Justin M Jones

Doctor of Pharmacy, Pharmacy Department, Sanford Medical Center Fargo, Fargo, ND, USA

Andrea R Clarens

Doctor of Pharmacy Pharmacy Department, Sanford Bemidji Medical  Center, Bemidji, MN, USA

Key words

• Acute kidney injury
• Computed tomography

• Kidney Disease Improving Global Outcomes

• Negative pressure wound therapy

Declaration Emily Greenstein reports she has been a consultant for Urgo medical, 3M and Coloplast. 3M manufactures V. A.C VeraFlo. None of these manufacture or distribute vancomycin instillation described in this manuscript.

Do peripheral arterial disease and smoking impede diabetic ulcer healing?

Background: In some patients, diabetic foot ulcers may heal slowly despite tight control of blood glucose and normal limb circulation, implying the presence of multifactorial, unidentified factors to wound healing. Previous efforts to identify these factors using binary variables, such as amputation or specific healing timelines, inadequately reflect the complexities of wound healing capacity.

Aims: We aimed to identify factors associated with delayed diabetic foot ulcer healing.

Methods: Eight factors were assumed to affect diabetic foot ulcer healing; patient age, age at the onset of diabetes, sex, peripheral arterial disease (PAD), HbA1c, smoking as measured by the Brinkman index (BI), dialysis and bone infection. They were analysed using linear regression and multivariable analysis against three healing indices: total healing period (THP), granulation time (GT) and time to contraction onset (TCO).

Results: PAD and BI correlated positively with all three indices. Patients with PAD exhibited significantly extended THP, GT and TCO. An increase of 100 in BI corresponded with a 1.53 day increase in GT. Conclusion: PAD was associated with delayed healing according to every measure analysed, while BI was linked with slower granulation. Besides THP, the measurements of GT — and possibly TCO — could evaluate some aspects of healing capacity of diabetic ulcers.

Kazufumi Tachi

Senior Lecturer, Division of Plastic Surgery, Tohoku Medical and Pharmaceutical University, Sendai, Japan

Koichi Gonda

Professor, Division of Plastic Surgery, Tohoku Medical and Pharmaceutical University, Sendai, Japan

Takashi Kochi

Chief Surgeon, Department of Plastic Surgery, Sendai City Hospital, Sendai, Japan

Jyunya Niwa

Research Associate, Division of Plastic Surgery, Tohoku Medical and Pharmaceutical University, Sendai, Japan

Key words

Diabetic foot ulcer

New index of wound healing

Brinkman index

Declarations

All authors have no conflicts of interest to declare.